Table 2. Data inputs used for NMA Trial... | American Society of Hematology

Table 2.

Data inputs used for NMA

Trial	Comparators	High risk∗					del(17p)		TP53 mutation
		n	OR (95% CI)		HR (95% CI)		n	HR (95% CI)	n	HR (95% CI)
		n	ORR-INV	CR-INV	PFS-INV	OS	n	PFS-INV	n	PFS-INV
ALPINE, adjusted	Zanubrutinib	75	3.02 (1.35-6.73)	1.89 (0.53-6.75)	0.49 (0.31-0.78)	0.59 (0.31-1.12)	45	0.49 (0.27-0.89)	50	0.49 (0.28-0.86)
	Ibrutinib	75	Ref	Ref	Ref	Ref	50	Ref	45	Ref
ALPINE, unadjusted	Zanubrutinib	75	2.64 (1.07-6.54)	1.67 (0.52-5.37)	0.52 (0.33-0.82)	0.69 (0.38-1.24)	45	0.53 (0.30-0.94)	50	0.52 (0.30-0.90)
	Ibrutinib	75	Ref	Ref	Ref	Ref	50	Ref	45	Ref
ELEVATE-RR	Acalabrutinib	268	1.61 (1.01-2.56)	0.95 (0.53-1.68)	0.90 (0.70-1.16)	0.82 (0.58-1.15)	124	1.00 (0.73-1.37)	100	0.95 (0.68-1.33)
	Ibrutinib	265	Ref	Ref	Ref	Ref	121	Ref	112	Ref
ASCEND	Acalabrutinib	44	NR	NR	0.22 (0.12-0.40)	0.90 (0.45-1.79)	28	0.13 (0.06-0.29)	39	0.25 (0.14-0.45)
	BR/IR	42	NR	NR	Ref	Ref	21	Ref	34	Ref

Trial	Comparators	High risk∗					del(17p)		TP53 mutation
		n	OR (95% CI)		HR (95% CI)		n	HR (95% CI)	n	HR (95% CI)
		n	ORR-INV	CR-INV	PFS-INV	OS	n	PFS-INV	n	PFS-INV
ALPINE, adjusted	Zanubrutinib	75	3.02 (1.35-6.73)	1.89 (0.53-6.75)	0.49 (0.31-0.78)	0.59 (0.31-1.12)	45	0.49 (0.27-0.89)	50	0.49 (0.28-0.86)
	Ibrutinib	75	Ref	Ref	Ref	Ref	50	Ref	45	Ref
ALPINE, unadjusted	Zanubrutinib	75	2.64 (1.07-6.54)	1.67 (0.52-5.37)	0.52 (0.33-0.82)	0.69 (0.38-1.24)	45	0.53 (0.30-0.94)	50	0.52 (0.30-0.90)
	Ibrutinib	75	Ref	Ref	Ref	Ref	50	Ref	45	Ref
ELEVATE-RR	Acalabrutinib	268	1.61 (1.01-2.56)	0.95 (0.53-1.68)	0.90 (0.70-1.16)	0.82 (0.58-1.15)	124	1.00 (0.73-1.37)	100	0.95 (0.68-1.33)
	Ibrutinib	265	Ref	Ref	Ref	Ref	121	Ref	112	Ref
ASCEND	Acalabrutinib	44	NR	NR	0.22 (0.12-0.40)	0.90 (0.45-1.79)	28	0.13 (0.06-0.29)	39	0.25 (0.14-0.45)
	BR/IR	42	NR	NR	Ref	Ref	21	Ref	34	Ref

Ref, reference for the HR.

Trial-defined definition of high risk.